Repository logo
 
Publication

Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage

2009Journal article Open access
Simple item page
dc.contributor.authorCosta, Elísio
dc.contributor.authorBelo, Luís
dc.contributor.authorQuintanilha, Alexandre
dc.contributor.authorSantos-Silva, Alice
dc.date.accessioned2010-10-16T16:46:14Z
dc.date.available2010-10-16T16:46:14Z
dc.date.issued2009
dc.description.abstractAnaemia is a common complication in haemodialysis patients. This condition is associated to a decreased bone marrow production of erythrocytes, mainly due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anaemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anaemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy. rhEPO resistance is associated to an increased morbidity and mortality of haemodialysis patients. In this paper a revision of the mechanisms underlying resistance to rhEPO therapy will be performed, with particular emphasis on inflammatory cytokines, leukocyte activation, iron status, and erythrocyte damage.por
dc.identifier.citationCOSTA, Elísio; BELO, Luís - Resistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. Journal of Nephrology and Renal Transplantation. ISSN 1918-025X. Vol. 2, n.º 3 (2009), p. 66–83por
dc.identifier.urihttp://hdl.handle.net/10400.14/3025
dc.language.isoengpor
dc.publisherOmniScientiapor
dc.subjectHaemodialysispor
dc.subjectResitance to rhEPO therapypor
dc.subjectErythropoietinpor
dc.subjectInflammationpor
dc.subjectLeukocyte activationpor
dc.subjectIron statuspor
dc.subjectErythrocyte damagepor
dc.titleResistance to recombinant human erythropoietin therapy in haemodialysis patients: Focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damagepor
dc.typejournal article
dspace.entity.typePublication
person.familyNameBelo
person.givenNameLuís
person.identifier.ciencia-idC319-EED1-E15D
person.identifier.orcid0000-0002-3941-6850
person.identifier.ridK-5878-2013
person.identifier.scopus-author-id6602879850
rcaap.rightsopenAccesspor
rcaap.typearticlepor
relation.isAuthorOfPublication3654b7b5-7ad2-4f2f-9114-93dc094f8e9e
relation.isAuthorOfPublication.latestForDiscovery3654b7b5-7ad2-4f2f-9114-93dc094f8e9e

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
com-inter_2009_ICS_1630_Costa_Elisio_13.pdf
Size:
162.21 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCSE - Contribuições em Revistas Científicas / Contribution to Journals